- Home
- INVE vs WHWK Comparison
INVE vs WHWK Comparison
Compare INVE & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INVE | WHWK |
|---|---|---|
| Founded | 1990 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.8M | 95.2M |
| IPO Year | 1997 | N/A |
Fundamental Metrics
Financial Performance| Metric | INVE | WHWK |
|---|---|---|
| Price | $3.18 | $3.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $5.50 | ★ $7.00 |
| AVG Volume (30 Days) | 31.6K | ★ 124.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1182.76 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $60,219,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.82 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.21 | N/A |
| 52 Week Low | $2.86 | $1.39 |
| 52 Week High | $4.07 | $3.77 |
Technical Indicators
Market Signals| Indicator | INVE | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 51.21 | 61.53 |
| Support Level | $3.17 | $1.89 |
| Resistance Level | $3.49 | $3.77 |
| Average True Range (ATR) | 0.19 | 0.20 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 43.18 | 65.54 |
Price Performance
Historical ComparisonAbout INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.
About WHWK Whitehawk Therapeutics Inc.
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.